Recap: OptiNose Q1 Earnings

OptiNose (NASDAQ:OPTN) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:00 AM. Here’s what investors…

OptiNose (NASDAQ:OPTN) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

OptiNose missed estimated earnings by 21.43%, reporting an EPS of $-0.17 versus an estimate of $-0.14.

Revenue was down $2.91 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0 which was followed by a 2.15% increase in the share price the next day.

Here’s a look at OptiNose’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.17 -0.18 -0.24 -0.27
EPS Actual -0.17 -0.18 -0.23 -0.31
Revenue Estimate 20.69M 23.40M 20.60M 16.71M
Revenue Actual 20.86M 20.08M 20.58M 14.76M

To track all earnings releases for OptiNose visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Ultragenyx Reports Preliminary 2023 Revenue; Guidance For 2024 Revenue And Cash Usage; Pipeline Updates And 2024 Milestones; Sees FY23 Revenue $430-$435M Vs $435.9M Est.; Sees FY24 Revenue $500M-$530M Vs $523.86M Est.; Year-End 2023 Cash Balance Of ~$7…

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million2024 expected Total Revenue guidance

RARE